Abstract
The platelet-derived growth factor receptor β (PDGFRB) gene translocations lead to a spectrum of chronic myeloid neoplasms, frequently associated with eosinophilia. Clinical heterogeneity is associated with a molecular one. Here, we report a novel case of a patient harboring a t(5;8)(q33;p22) translocation, resulting in the PCM1/PDGFRB fusion. Conventional cytogenetics and RNA sequencing were performed to identify the chromosomes and the genes involved in the rearrangement, respectively. This study shows that the combination of different strategies is pivotal to fine-tune the diagnosis and the clinical management of the patient. After 1 year of treatment with imatinib, the patient achieves hematological and molecular remission. We present an attractive strategy to identify novel and/or cryptic fusions, which will be relevant for clinicians dealing with the diagnosis of the patients with myelodysplastic syndrome/myeloproliferative diseases with atypical manifestations.
References
1.
Arber
DA
, Orazi
A
, Hasserjian
R
, Thiele
J
, Borowitz
MJ
, Le Beau
MM
, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
. Blood
. 2016
May
;127
(20
):2391
–405
.
[PubMed]
0006-49712.
Reiter
A
, Walz
C
, Watmore
A
, Reiter
A
, Walz
C
, Watmore
A
, et al.: The t (8 ; 9) (p22 ; p24) Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM1 to JAK2 and Acute Leukemia that Fuses PCM1 to JAK2 2005
;2662–2667.3.
Jawhar
M
, Naumann
N
, Schwaab
J
, Baurmann
H
, Casper
J
, Dang
TA
, et al. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase
. Ann Hematol
. 2017
Sep
;96
(9
):1463
–70
.
[PubMed]
0939-55554.
Cheah
CY
, Burbury
K
, Apperley
JF
, Huguet
F
, Pitini
V
, Gardembas
M
, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib
. Blood
. 2014
Jun
;123
(23
):3574
–7
.
[PubMed]
0006-49715.
Jawhar
M
, Naumann
N
, Knut
M
, Score
J
, Ghazzawi
M
, Schneider
B
, et al. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia
. Leukemia
. 2017
Oct
;31
(10
):2271
–3
.
[PubMed]
0887-69246.
Stengel
A
, Nadarajah
N
, Haferlach
T
, Dicker
F
, Kern
W
, Meggendorfer
M
, et al. Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing
. Leukemia
. 2018
May
;32
(5
):1229
–38
.
[PubMed]
0887-69247.
Ghazzawi
M
, Mehra
V
, Knut
M
, Brown
L
, Tapper
W
, Chase
A
, et al. A Novel PCM1-PDGFRB Fusion in a Patient with a Chronic Myeloproliferative Neoplasm and an ins(8;5)
. Acta Haematol
. 2017
;138
(4
):198
–200
.
[PubMed]
0001-57928.
Reiter
A
, Walz
C
, Watmore
A
, Schoch
C
, Blau
I
, Schlegelberger
B
, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
. Cancer Res
. 2005
Apr
;65
(7
):2662
–7
.
[PubMed]
0008-54729.
Such
E
, Germing
U
, Malcovati
L
, Cervera
J
, Kuendgen
A
, Della Porta
MG
, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia
. Blood
. 2013
Apr
;121
(15
):3005
–15
.
[PubMed]
0006-497110.
Such
, Esperanza
; Solé
, Francesc
; Vázquez
, Iria
; Abáigar
, María
; Tazón
, Barbara
; Rapado
, Inmaculada
; Cabezón
, Marta
; Álvarez S: Guía de Aplicación Clínica de la Secuenciación masiva en Síndromes Mielodisplásicos y Leucemia Mielomonocítica Crónica 2017
;6291.11.
Dobin
A
, Davis
CA
, Schlesinger
F
, Drenkow
J
, Zaleski
C
, Jha
S
, et al. STAR: ultrafast universal RNA-seq aligner
. Bioinformatics
. 2013
Jan
;29
(1
):15
–21
.
[PubMed]
1367-480312.
Kim
D
, Salzberg
SL
. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts
. Genome Biol
. 2011
Aug
;12
(8
):R72
.
[PubMed]
1474-759613.
Haas
B
, Dobin
A
, Stransky
N
, Li
B
, Yang
X
, Tickle
T
, et al. STAR-Fusion: Fast and Accurate Fusion Transcript Detection from RNA-Seq
. bioRxiv
. 2017
;•••
:120295
.14.
Andrae
J
, Gallini
R
, Betsholtz
C
: Role of platelet-derived growth factors in physiology and medicine
. 2008
;1276–1312. 15.
Swerdlow
SH
, Campo
E
, Harris
NL
, Jaffe
ES
, Pileri
SA
, Stein
HT
. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
. Revised 4th edition. 2017
.16.
Byrgazov
K
, Gorna
M
, Hoermann
G
, Koenig
M
, Ulreich
R
, Benesch
M
, et al. NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors
. Leukemia
. 2016
;•••
:1
–13
.
[PubMed]
0887-692417.
Hoang-Minh
LB
, Deleyrolle
LP
, Nakamura
NS
, Parker
AK
, Martuscello
RT
, Reynolds
BA
, et al. PCM1 Depletion Inhibits Glioblastoma Cell Ciliogenesis and Increases Cell Death and Sensitivity to Temozolomide
. Transl Oncol
. 2016
Oct
;9
(5
):392
–402
.
[PubMed]
1936-5233© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
